Drug Type Small molecule drug |
Synonyms AZD 0780, AZD-0780, AZD0780 |
Target |
Action inhibitors |
Mechanism PCSK9 inhibitors(Proprotein convertase subtilisin kexin type 9 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H20F2N6O2 |
InChIKeyNCHUWRLOTSAFFN-KBPBESRZSA-N |
CAS Registry2455427-91-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Heterozygous familial hypercholesterolemia | Phase 3 | United States | 10 Jun 2025 | |
Heterozygous familial hypercholesterolemia | Phase 3 | Japan | 10 Jun 2025 | |
Heterozygous familial hypercholesterolemia | Phase 3 | Argentina | 10 Jun 2025 | |
Heterozygous familial hypercholesterolemia | Phase 3 | Australia | 10 Jun 2025 | |
Heterozygous familial hypercholesterolemia | Phase 3 | Brazil | 10 Jun 2025 | |
Heterozygous familial hypercholesterolemia | Phase 3 | Bulgaria | 10 Jun 2025 | |
Heterozygous familial hypercholesterolemia | Phase 3 | Canada | 10 Jun 2025 | |
Heterozygous familial hypercholesterolemia | Phase 3 | Chile | 10 Jun 2025 | |
Heterozygous familial hypercholesterolemia | Phase 3 | Czechia | 10 Jun 2025 | |
Heterozygous familial hypercholesterolemia | Phase 3 | Denmark | 10 Jun 2025 |
Phase 2 | 426 | kiflckbsww(tftsbgcinr) = kwrlkdscmr bacucuafhu (rwohpijfyc ) | Positive | 27 Mar 2025 | |||
AZD0780 1mg | wyqqifsrrh(efkbcjrryf) = cokiyfouan hsjzremyjc (gwimptkmuo ) | ||||||
Phase 1 | - | kwqblcywbj(ucunjitzfn) = None jhlfpuaiyc (fhngtypyxr ) | Positive | 29 May 2024 |